Pictet Asset Management SA Has $184.22 Million Position in Boston Scientific Co. (NYSE:BSX)

Pictet Asset Management SA raised its holdings in Boston Scientific Co. (NYSE:BSXGet Rating) by 5.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,336,696 shares of the medical equipment provider’s stock after buying an additional 205,258 shares during the period. Pictet Asset Management SA owned 0.30% of Boston Scientific worth $184,223,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of BSX. Industrial Alliance Investment Management Inc. acquired a new position in shares of Boston Scientific during the 4th quarter worth about $262,000. Rafferty Asset Management LLC increased its stake in shares of Boston Scientific by 5.5% during the 4th quarter. Rafferty Asset Management LLC now owns 47,895 shares of the medical equipment provider’s stock worth $2,035,000 after purchasing an additional 2,498 shares during the last quarter. Capital Analysts LLC increased its stake in shares of Boston Scientific by 2.1% during the 4th quarter. Capital Analysts LLC now owns 54,382 shares of the medical equipment provider’s stock worth $2,310,000 after purchasing an additional 1,135 shares during the last quarter. Tredje AP fonden increased its stake in shares of Boston Scientific by 16.9% during the 4th quarter. Tredje AP fonden now owns 256,742 shares of the medical equipment provider’s stock worth $10,906,000 after purchasing an additional 37,153 shares during the last quarter. Finally, TD Asset Management Inc. increased its stake in shares of Boston Scientific by 2.2% during the 4th quarter. TD Asset Management Inc. now owns 552,858 shares of the medical equipment provider’s stock worth $23,485,000 after purchasing an additional 11,643 shares during the last quarter. Hedge funds and other institutional investors own 90.48% of the company’s stock.

Several research firms have recently weighed in on BSX. TheStreet lowered shares of Boston Scientific from a “b” rating to a “c+” rating in a research note on Tuesday, March 8th. Morgan Stanley reduced their target price on shares of Boston Scientific from $53.00 to $51.00 and set an “overweight” rating for the company in a report on Thursday, February 3rd. Raymond James reduced their target price on shares of Boston Scientific from $51.00 to $49.00 and set a “strong-buy” rating for the company in a report on Thursday, February 3rd. Bank of America initiated coverage on shares of Boston Scientific in a report on Tuesday, March 1st. They set a “buy” rating for the company. Finally, StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Thursday, April 21st. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Boston Scientific presently has an average rating of “Buy” and an average price target of $49.17.

In other news, CFO Daniel J. Brennan sold 53,182 shares of the company’s stock in a transaction that occurred on Tuesday, February 22nd. The shares were sold at an average price of $42.75, for a total transaction of $2,273,530.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Daniel J. Brennan sold 12,187 shares of the company’s stock in a transaction that occurred on Wednesday, February 16th. The stock was sold at an average price of $43.70, for a total transaction of $532,571.90. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 108,576 shares of company stock valued at $4,725,374. 0.71% of the stock is currently owned by insiders.

NYSE BSX opened at $39.66 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.48 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $56.70 billion, a P/E ratio of 74.83, a P/E/G ratio of 2.23 and a beta of 0.81. Boston Scientific Co. has a 12-month low of $37.96 and a 12-month high of $47.49. The firm has a 50-day moving average price of $43.12 and a two-hundred day moving average price of $42.67.

Boston Scientific (NYSE:BSXGet Rating) last posted its quarterly earnings data on Wednesday, April 27th. The medical equipment provider reported $0.39 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.39. The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $2.95 billion. Boston Scientific had a net margin of 6.65% and a return on equity of 14.60%. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.37 EPS. Equities analysts expect that Boston Scientific Co. will post 1.76 EPS for the current year.

Boston Scientific Profile (Get Rating)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

Further Reading

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.